{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T01:19:27Z","timestamp":1787534367872,"version":"build-2736575974"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":75,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-56211-3","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T13:15:26Z","timestamp":1781097326000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ex vivo evaluation of Newcastle disease virus to enhance natural killer cell function against acute myeloid leukemia cells"],"prefix":"10.1038","volume":"16","author":[{"given":"Shima","family":"Tavoosi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheila","family":"Rahgozar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ahmadvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Jarahian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayhan","family":"Azadmanesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"56211_CR1","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","volume":"98","author":"S Shimony","year":"2023","unstructured":"Shimony, S., Stahl, M. & Stone, R. M. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 98, 502\u2013526 (2023).","journal-title":"Am. J. Hematol."},{"key":"56211_CR2","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner, H., Weisdorf, D. J. & Bloomfield, C. D. Acute myeloid leukemia. N. Engl. J. Med. 373, 1136\u20131152 (2015).","journal-title":"N. Engl. J. Med."},{"key":"56211_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","volume":"21","author":"F Thol","year":"2020","unstructured":"Thol, F. & Ganser, A. Treatment of relapsed acute myeloid leukemia. Curr. Treat. Options Oncol. 21, 66 (2020).","journal-title":"Curr. Treat. Options Oncol."},{"key":"56211_CR4","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/ajh.25162","volume":"93","author":"C Ganzel","year":"2018","unstructured":"Ganzel, C. et al. Very poor long-term survival in past and more recent studies for relapsed AML patients: the ECOG\u2010ACRIN experience. Am. J. Hematol. 93, 1074\u20131081 (2018).","journal-title":"Am. J. Hematol."},{"key":"56211_CR5","doi-asserted-by":"publisher","first-page":"116132","DOI":"10.1016\/j.biopha.2024.116132","volume":"171","author":"Y Wu","year":"2024","unstructured":"Wu, Y. et al. Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective. Biomed. Pharmacother. 171, 116132 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"56211_CR6","doi-asserted-by":"publisher","first-page":"1192907","DOI":"10.3389\/fimmu.2023.1192907","volume":"14","author":"E Shin","year":"2023","unstructured":"Shin, E. et al. Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond. Front. Immunol. 14, 1192907 (2023).","journal-title":"Front. Immunol."},{"key":"56211_CR7","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/eji.202049028","volume":"51","author":"L Quatrini","year":"2021","unstructured":"Quatrini, L. et al. Human NK cells, their receptors and function. Eur. J. Immunol. 51, 1566\u20131579 (2021).","journal-title":"Eur. J. Immunol."},{"key":"56211_CR8","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1007\/s00262-022-03217-1","volume":"71","author":"S Rahmani","year":"2022","unstructured":"Rahmani, S., Yazdanpanah, N. & Rezaei, N. Natural killer cells and acute myeloid leukemia: promises and challenges. Cancer Immunol. Immunother. 71, 2849\u20132867 (2022).","journal-title":"Cancer Immunol. Immunother."},{"key":"56211_CR9","doi-asserted-by":"publisher","first-page":"1112059","DOI":"10.3389\/fimmu.2023.1112059","volume":"14","author":"SZ D\u2019Silva","year":"2023","unstructured":"D\u2019Silva, S. Z., Singh, M. & Pinto, A. NK cell defects: implication in acute myeloid leukemia. Front. Immunol. 14, 1112059 (2023).","journal-title":"Front. Immunol."},{"key":"56211_CR10","doi-asserted-by":"publisher","first-page":"1111419","DOI":"10.3389\/fimmu.2023.1111419","volume":"14","author":"R Meazza","year":"2023","unstructured":"Meazza, R. et al. Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire. Front. Immunol. 14, 1111419 (2023).","journal-title":"Front. Immunol."},{"key":"56211_CR11","doi-asserted-by":"crossref","unstructured":"Kaito, Y. & Imai, Y. Evolution of natural killer cell-targeted therapy for acute myeloid leukemia. Int. J. Hematol., 1\u201310 (2024).","DOI":"10.1007\/s12185-024-03778-0"},{"key":"56211_CR12","doi-asserted-by":"publisher","first-page":"910595","DOI":"10.3389\/fimmu.2022.910595","volume":"13","author":"B Seliger","year":"2022","unstructured":"Seliger, B. & Koehl, U. Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies. Front. Immunol. 13, 910595 (2022).","journal-title":"Front. Immunol."},{"key":"56211_CR13","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41586-019-1410-1","volume":"572","author":"AM Paczulla","year":"2019","unstructured":"Paczulla, A. M. et al. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature 572, 254\u2013259 (2019).","journal-title":"Nature"},{"key":"56211_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-021-02277-x","volume":"12","author":"MG Lamb","year":"2021","unstructured":"Lamb, M. G., Rangarajan, H. G., Tullius, B. P. & Lee, D. A. Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future. Stem Cell Res. Ther. 12, 1\u201319 (2021).","journal-title":"Stem Cell Res. Ther."},{"key":"56211_CR15","doi-asserted-by":"crossref","unstructured":"Li, Z. et al. Enhanced oncolytic potential of engineered newcastle disease virus lasota strain through modification of its F protein cleavage site. Microorganisms 12, 2029 (2024).","DOI":"10.3390\/microorganisms12102029"},{"key":"56211_CR16","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.3390\/life13081626","volume":"13","author":"U Pathak","year":"2023","unstructured":"Pathak, U., Pal, R. B. & Malik, N. The viral knock: ameliorating cancer treatment with oncolytic Newcastle disease virus. Life 13, 1626 (2023).","journal-title":"Life"},{"key":"56211_CR17","doi-asserted-by":"crossref","unstructured":"Najmuddin, S. U. F. S. et al. A mini-review on oncolytic newcastle disease virus (NDV): From highly contagious virus to a biological tool for cancer therapy. The Open. Biotechnol. J. 17 (2023).","DOI":"10.2174\/0118740707264166231013051006"},{"key":"56211_CR18","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3390\/biomedicines10030562","volume":"10","author":"V Schirrmacher","year":"2022","unstructured":"Schirrmacher, V. Molecular mechanisms of anti-neoplastic and immune stimulatory properties of oncolytic Newcastle disease virus. Biomedicines 10, 562 (2022).","journal-title":"Biomedicines"},{"key":"56211_CR19","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3389\/fimmu.2019.00909","volume":"10","author":"AD Barrow","year":"2019","unstructured":"Barrow, A. D., Martin, C. J. & Colonna, M. The natural cytotoxicity receptors in health and disease. Front. Immunol. 10, 909 (2019).","journal-title":"Front. Immunol."},{"key":"56211_CR20","doi-asserted-by":"publisher","first-page":"8108","DOI":"10.1128\/JVI.00211-09","volume":"83","author":"M Jarahian","year":"2009","unstructured":"Jarahian, M. et al. Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. J. Virol. 83, 8108\u20138121 (2009).","journal-title":"J. Virol."},{"key":"56211_CR21","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3390\/cells9030753","volume":"9","author":"L Zamai","year":"2020","unstructured":"Zamai, L. et al. Understanding the synergy of NKp46 and co-activating signals in various NK cell subpopulations: paving the way for more successful NK-cell-based immunotherapy. Cells 9, 753 (2020).","journal-title":"Cells"},{"key":"56211_CR22","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.3390\/cancers12123586","volume":"12","author":"Y Yang","year":"2020","unstructured":"Yang, Y. & Lundqvist, A. Immunomodulatory effects of IL-2 and IL-15; implications for cancer immunotherapy. Cancers 12, 3586 (2020).","journal-title":"Cancers"},{"key":"56211_CR23","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3390\/cells13050451","volume":"13","author":"A Maia","year":"2024","unstructured":"Maia, A. et al. Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy. Cells 13, 451 (2024).","journal-title":"Cells"},{"key":"56211_CR24","doi-asserted-by":"publisher","first-page":"802906","DOI":"10.3389\/fimmu.2022.802906","volume":"13","author":"M Gurney","year":"2022","unstructured":"Gurney, M., Kundu, S., Pandey, S. & O\u2019Dwyer, M. Feeder cells at the interface of natural killer cell activation, expansion and gene editing. Front. Immunol. 13, 802906 (2022).","journal-title":"Front. Immunol."},{"key":"56211_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers, J. A. & Miller, J. S. Exploring the NK cell platform for cancer immunotherapy. Nat. reviews Clin. Oncol. 18, 85\u2013100 (2021).","journal-title":"Nat. reviews Clin. Oncol."},{"key":"56211_CR26","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.3389\/fimmu.2019.02357","volume":"10","author":"M Carlsten","year":"2019","unstructured":"Carlsten, M. & J\u00e4r\u00e5s, M. Natural killer cells in myeloid malignancies: immune surveillance, NK cell dysfunction, and pharmacological opportunities to bolster the endogenous NK cells. Front. Immunol. 10, 2357 (2019).","journal-title":"Front. Immunol."},{"key":"56211_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-021-00265-0","volume":"9","author":"R Guo","year":"2021","unstructured":"Guo, R. et al. Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment. Biomark. Res. 9, 1\u201316 (2021).","journal-title":"Biomark. Res."},{"key":"56211_CR28","doi-asserted-by":"publisher","first-page":"6204","DOI":"10.4049\/jimmunol.208.Supp.62.04","volume":"208","author":"V Kuznetsova","year":"2022","unstructured":"Kuznetsova, V. et al. Perturbed function of natural killer cells by inflammatory cytokines in acute (AML) and chronic (CML) myeloid leukemias. J. Immunol. 208, 6204\u20136204 (2022).","journal-title":"J. Immunol."},{"key":"56211_CR29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40164-024-00561-z","volume":"13","author":"Y Shi","year":"2024","unstructured":"Shi, Y., Hao, D., Qian, H. & Tao, Z. Natural killer cell-based cancer immunotherapy: from basics to clinical trials. Experimental Hematol. Oncol. 13, 101 (2024).","journal-title":"Experimental Hematol. Oncol."},{"key":"56211_CR30","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12967-022-03437-0","volume":"20","author":"J Chu","year":"2022","unstructured":"Chu, J. et al. Natural killer cells: a promising immunotherapy for cancer. J. translational Med. 20, 240 (2022).","journal-title":"J. translational Med."},{"key":"56211_CR31","doi-asserted-by":"publisher","first-page":"5377","DOI":"10.3390\/ijms24065377","volume":"24","author":"R Skopek","year":"2023","unstructured":"Skopek, R. et al. Choosing the right cell line for acute myeloid leukemia (AML) research. Int. J. Mol. Sci. 24, 5377 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"56211_CR32","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.3390\/ijms20143472","volume":"20","author":"M Holubova","year":"2019","unstructured":"Holubova, M. et al. Improving the clinical application of natural killer cells by modulating signals signal from target cells. Int. J. Mol. Sci. 20, 3472 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"56211_CR33","first-page":"918","volume":"14","author":"S Tavakoli","year":"2024","unstructured":"Tavakoli, S. et al. Cell Therapy Using Anti-NKG2A Pretreated Natural Killer Cells in Patients with Hepatocellular Carcinoma. Adv. Pharm. Bull. 14, 918 (2024).","journal-title":"Adv. Pharm. Bull."},{"key":"56211_CR34","unstructured":"Raedler, L. A. Imlygic (Talimogene Laherparepvec): First oncolytic viral therapy for the treatment of patients with recurrent melanoma. (2016)."},{"key":"56211_CR35","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.1038\/s41598-020-61736-2","volume":"10","author":"QA Alayo","year":"2020","unstructured":"Alayo, Q. A. et al. Glioblastoma infiltration of both tumor-and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses. Sci. Rep. 10, 5095 (2020).","journal-title":"Sci. Rep."},{"key":"56211_CR36","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1038\/s41375-020-0828-7","volume":"34","author":"N Packiriswamy","year":"2020","unstructured":"Packiriswamy, N. et al. Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma. Leukemia 34, 3310\u20133322 (2020).","journal-title":"Leukemia"},{"key":"56211_CR37","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.3390\/ijms18051103","volume":"18","author":"V Schirrmacher","year":"2017","unstructured":"Schirrmacher, V. Immunobiology of Newcastle disease virus and its use for prophylactic vaccination in poultry and as adjuvant for therapeutic vaccination in cancer patients. Int. J. Mol. Sci. 18, 1103 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"56211_CR38","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12943-022-01664-z","volume":"21","author":"Z Zhu","year":"2022","unstructured":"Zhu, Z. et al. Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways. Mol. Cancer. 21, 196 (2022).","journal-title":"Mol. Cancer"},{"key":"56211_CR39","first-page":"1349","volume":"11","author":"H Mirzaee","year":"2024","unstructured":"Mirzaee, H., Mirzaei Nodooshan, M., Malekara, E., Farzanehpour, M. & Vakilzade, G. An Overview of Newcastle Disease Virus as a Potential Anti-cancer Agent for Gastrointestinal Cancer. J. Appl. Biotechnol. Rep. 11, 1349\u20131358 (2024).","journal-title":"J. Appl. Biotechnol. Rep."},{"key":"56211_CR40","doi-asserted-by":"publisher","first-page":"284","DOI":"10.14218\/JCTH.2021.00284","volume":"10","author":"L Chen","year":"2021","unstructured":"Chen, L. et al. Oncolytic activity of wild-type Newcastle disease virus HK84 against hepatocellular carcinoma associated with activation of type I interferon signaling. J. Clin. Translational Hepatol. 10, 284 (2021).","journal-title":"J. Clin. Translational Hepatol."},{"key":"56211_CR41","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1128\/JVI.02618-05","volume":"80","author":"S Krishnamurthy","year":"2006","unstructured":"Krishnamurthy, S., Takimoto, T., Scroggs, R. A. & Portner, A. Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J. Virol. 80, 5145\u20135155 (2006).","journal-title":"J. Virol."},{"key":"56211_CR42","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/ijc.21821","volume":"119","author":"C Fiola","year":"2006","unstructured":"Fiola, C. et al. Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int. J. Cancer. 119, 328\u2013338 (2006).","journal-title":"Int. J. Cancer"},{"key":"56211_CR43","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.3390\/cancers12123552","volume":"12","author":"B Burman","year":"2020","unstructured":"Burman, B., Pesci, G. & Zamarin, D. Newcastle disease virus at the forefront of cancer immunotherapy. Cancers 12, 3552 (2020).","journal-title":"Cancers"},{"key":"56211_CR44","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1080\/21645515.2020.1723363","volume":"16","author":"M Mondal","year":"2020","unstructured":"Mondal, M., Guo, J., He, P. & Zhou, D. Recent advances of oncolytic virus in cancer therapy. Hum. vaccines immunotherapeutics. 16, 2389\u20132402 (2020).","journal-title":"Hum. vaccines immunotherapeutics"},{"key":"56211_CR45","doi-asserted-by":"publisher","first-page":"100639","DOI":"10.1016\/j.currproblcancer.2020.100639","volume":"45","author":"NH Goradel","year":"2021","unstructured":"Goradel, N. H. et al. Oncolytic virotherapy: Challenges and solutions. Curr. Probl. Cancer. 45, 100639 (2021).","journal-title":"Curr. Probl. Cancer"},{"key":"56211_CR46","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/vms3.629","volume":"8","author":"M Shafaati","year":"2022","unstructured":"Shafaati, M., Ghorbani, M., Mahmodi, M., Ebadi, M. & Jalalirad, R. Molecular evaluation and genetic characterisation of Newcastle disease virus\u2019s haemagglutinin-neuraminidase protein isolated from broiler chickens in Iran. Veterinary Med. Sci. 8, 219\u2013228 (2022).","journal-title":"Veterinary Med. Sci."},{"key":"56211_CR47","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1128\/JVI.78.7.3733-3741.2004","volume":"78","author":"V Zaitsev","year":"2004","unstructured":"Zaitsev, V. et al. Second sialic acid binding site in Newcastle disease virus hemagglutinin-neuraminidase: implications for fusion. J. Virol. 78, 3733\u20133741 (2004).","journal-title":"J. Virol."},{"key":"56211_CR48","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/onc.2014.7","volume":"34","author":"H Ma","year":"2015","unstructured":"Ma, H. et al. Modification of sialylation is associated with multidrug resistance in human acute myeloid leukemia. Oncogene 34, 726\u2013740 (2015).","journal-title":"Oncogene"},{"key":"56211_CR49","doi-asserted-by":"publisher","first-page":"107762","DOI":"10.1016\/j.intimp.2021.107762","volume":"96","author":"MB Shapourabadi","year":"2021","unstructured":"Shapourabadi, M. B. et al. Bi\/tri-specific antibodies (HN-Fc-CD16 and HN-Fc-IL-15-CD16) cross-linking natural killer (NK)-CD16 and Newcastle Disease Virus (NDV)-HN, enhanced NK activation for cancer immunotherapy. Int. Immunopharmacol. 96, 107762 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"56211_CR50","doi-asserted-by":"publisher","first-page":"889403","DOI":"10.3389\/fmolb.2022.889403","volume":"9","author":"F Huang","year":"2022","unstructured":"Huang, F. et al. Development of molecular mechanisms and their application on oncolytic Newcastle disease virus in cancer therapy. Front. Mol. Biosci. 9, 889403 (2022).","journal-title":"Front. Mol. Biosci."},{"key":"56211_CR51","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1002\/jcb.25917","volume":"118","author":"S Ebrahimi","year":"2017","unstructured":"Ebrahimi, S. et al. Interferon-mediated tumor resistance to oncolytic virotherapy. J. Cell. Biochem. 118, 1994\u20131999 (2017).","journal-title":"J. Cell. Biochem."},{"key":"56211_CR52","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3233\/CBM-230033","volume":"38","author":"Z Nejatipour","year":"2023","unstructured":"Nejatipour, Z. et al. Looking for biomarkers in interferon response pathway to predict response to oncolytic HSV-1 in breast cancer: An ex vivo study. Cancer Biomarkers. 38, 37\u201347 (2023).","journal-title":"Cancer Biomarkers"},{"key":"56211_CR53","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1038\/s41467-024-45916-6","volume":"15","author":"B Wang","year":"2024","unstructured":"Wang, B. et al. Comprehensive characterization of IFN\u03b3 signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies. Nat. Commun. 15, 1821 (2024).","journal-title":"Nat. Commun."},{"key":"56211_CR54","doi-asserted-by":"crossref","unstructured":"Mah, A. Y. & Cooper, M. A. Metabolic regulation of natural killer cell IFN-\u03b3 production. Crit. Rev. Immunol. 36 (2016).","DOI":"10.1615\/CritRevImmunol.2016017387"},{"key":"56211_CR55","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1073\/pnas.1012356108","volume":"108","author":"A De Maria","year":"2011","unstructured":"De Maria, A., Bozzano, F., Cantoni, C. & Moretta, L. Revisiting human natural killer cell subset function revealed cytolytic CD56dimCD16\u2009+\u2009NK cells as rapid producers of abundant IFN-\u03b3 on activation. Proc. Natl. Acad. Sci. 108, 728\u2013732 (2011).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"56211_CR56","doi-asserted-by":"publisher","first-page":"1275028","DOI":"10.3389\/fimmu.2023.1275028","volume":"14","author":"H Jiang","year":"2023","unstructured":"Jiang, H. & Jiang, J. Balancing act: The complex role of NK cells in immune regulation. Front. Immunol. 14, 1275028 (2023).","journal-title":"Front. Immunol."},{"key":"56211_CR57","doi-asserted-by":"publisher","first-page":"1595533","DOI":"10.3389\/fimmu.2025.1595533","volume":"16","author":"M Chen","year":"2025","unstructured":"Chen, M. et al. Recent advances in tumor immunotherapy based on NK cells. Front. Immunol. 16, 1595533 (2025).","journal-title":"Front. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56211-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56211-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56211-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T01:02:08Z","timestamp":1787533328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56211-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["56211"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-56211-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"26437"}}